{"id":"F2021L01626","name":"Statement of Principles concerning chronic solvent-induced neurocognitive disorder (Reasonable Hypothesis) (No. 109 of 2021)","slug":"statement-of-principles-concerning-chronic-solvent-induced-neurocognitive-disorder-reasonable-hypoth","collection":"legislative_instrument","jurisdiction":"commonwealth","status":"in_force","isInForce":true,"actNumber":null,"makingDate":null,"administeringDepartment":null,"currentVersion":{"id":441074,"registerId":"F2021L01626-fast-fetch-1775956487346","compilationNumber":null,"startDate":"2026-04-12","status":"InForce","reasons":null,"registeredAt":null},"sections":[{"sectionNumber":"1","sectionType":"section","heading":"Statement of Principles concerning chronic solvent-induced neurocognitive disorder (Reasonable Hypothesis) (No. 109 of 2021)","content":"---\nmeta-content-style-type: text/css\nmeta-content-type: application/xhtml+xml; charset=utf-8\nmeta-generator: Aspose.Words for .NET 20.2\n---\n\n?xml version=\"1.0\" encoding=\"utf-8\" standalone=\"no\"?>\n\n\n\n \n\nStatement of Principles\n\nconcerning\n\nCHRONIC SOLVENT-INDUCED NEUROCOGNITIVE DISORDER (Reasonable Hypothesis)\n\n(No. 109 of 2021)\n\nThe Repatriation Medical Authority determines the following Statement of Principles under subsection 196B(2) of the Veterans' Entitlements Act 1986.\n\n \n\nDated 26 November 2021\n\n \n\n \n\n \n\n \n\n \n\n| The Common Seal of the Repatriation Medical Authority was affixed to this instrument at the direction of:
|\n| --- |\n|
Professor Terence Campbell AM
Chairperson
|\n\n\n \n\n \n\n\nContents\n\n1 Name\n\n2 Commencement\n\n3 Authority\n\n4 Repeal\n\n5 Application\n\n6 Definitions\n\n7 Kind of injury, disease or death to which this Statement of Principles relates\n\n8 Basis for determining the factors\n\n9 Factors that must exist\n\n10 Relationship to service\n\n11 Factors referring to an injury or disease covered by another Statement of Principles\n\nSchedule 1 - Dictionary\n\n1 Definitions\n\n \n\n\n\n\n1 Name\n\nThis is the Statement of Principles concerning chronic solvent-induced neurocognitive disorder (Reasonable Hypothesis) (No. 109 of 2021).\n\n2 Commencement\n\n This instrument commences on 20 December 2021.\n\n3 Authority\n\nThis instrument is made under subsection 196B(2) of the Veterans' Entitlements Act 1986.\n\n4 Repeal\n\nThe Statement of Principles concerning chronic solvent encephalopathy No. 71 of 2013 (Federal Register of Legislation No. F2013L01886) made under subsection 196B(2) of the VEA is repealed.\n\n5 Application\n\nThis instrument applies to a claim to which section 120A of the VEA or section 338 of the Military Rehabilitation and Compensation Act 2004 applies.\n\n6 Definitions\n\nThe terms defined in the Schedule 1 - Dictionary have the meaning given when used in this instrument.\n\n7 Kind of injury, disease or death to which this Statement of Principles relates\n\n(1) This Statement of Principles is about chronic solvent-induced neurocognitive disorder and death from chronic solvent-induced neurocognitive disorder.\n\nMeaning of chronic solvent-induced neurocognitive disorder\n\n(2) For the purposes of this Statement of Principles, chronic solvent-induced neurocognitive disorder:\n\n(a) means irreversible brain injury meeting the following diagnostic criteria:\n\n(i) evidence of significant cognitive decline from a previous level of performance in one or more cognitive domains (complex attention, executive function, learning and memory, language, perceptual-motor, or social cognition) based on:\n\n concern of the individual, a knowledgeable informant, or the clinician that there has been a significant decline in cognitive function; and\n\n a substantial impairment in cognitive performance, documented by standardised neuropsychological testing;\n\n(ii) the cognitive deficits interfere with independence in everyday activities;\n\n(iii) there must be evidence from the history, physical examination, or laboratory findings that the deficits are aetiologically related to the persisting neurological effects of organic solvents;\n\n(iv) the neurocognitive impairments do not occur exclusively during the course of a delirium and persist beyond the usual duration of intoxication and acute withdrawal;\n\n(v) the involved organic solvent and duration and extent of exposure are capable of producing the neurocognitive impairment;\n\n(vi) the temporal course of the neurocognitive deficits is consistent with the timing of organic solvent exposure; and\n\n(vii) the neurocognitive disorder is not attributable to another medical condition or is not better explained by another mental disorder; and\n\n(b) excludes alcohol-induced neurocognitive disorder and medication-induced neurocognitive disorder.\n\nNote 1: This definition is derived from the definition of substance-induced neurocognitive disorder contained in DSM-5.\n\nNote 2: DSM-5 is defined in the Schedule 1 - Dictionary.\n\nDeath from chronic solvent-induced neurocognitive disorder\n\n(3) For the purposes of this Statement of Principles, chronic solvent-induced neurocognitive disorder, in relation to a person, includes death from a terminal event or condition that was contributed to by the person's chronic solvent-induced neurocognitive disorder.\n\nNote: terminal event is defined in the Schedule 1 - Dictionary.\n\n8 Basis for determining the factors\n\nThe Repatriation Medical Authority is of the view that there is sound medical‑scientific evidence that indicates that chronic solvent-induced neurocognitive disorder and death from chronic solvent-induced neurocognitive disorder can be related to relevant service rendered by veterans, members of Peacekeeping Forces, or members of the Forces under the VEA, or members under the MRCA.\n\nNote: MRCA, relevant service and VEA are defined in the Schedule 1 - Dictionary.\n\n9 Factors that must exist\n\nAt least one of the following factors must as a minimum exist before it can be said that a reasonable hypothesis has been raised connecting chronic solvent-induced neurocognitive disorder or death from chronic solvent-induced neurocognitive disorder with the circumstances of a person's relevant service:\n\n(1) having a severe substance use disorder involving inhalation of a solvent from the Specified List 1 of solvents within the 5 years before the clinical onset of chronic solvent-induced neurocognitive disorder;\n\nNote: severe substance use disorder and Specified List 1 of solvents are defined in the Schedule 1 - Dictionary.\n\n(2) inhaling, ingesting or having cutaneous contact with a solvent from the Specified List 2 of solvents, where inhalation occurred in an unventilated and confined space, on more days than not for a consecutive period of at least 5 years before the clinical onset of chronic solvent-induced neurocognitive disorder, and if exposure has ceased before the clinical onset of chronic solvent-induced neurocognitive disorder, then that onset occurred within 1 year of cessation;\n\nNote: Specified List 2 of solvents is defined in the Schedule 1 - Dictionary.\n\n(3) having at least 50 episodes of acute solvent intoxication due to a solvent from the Specified List 2 of solvents within a consecutive period of 2 years before the clinical onset of chronic solvent-induced neurocognitive disorder, and where the last episode of acute solvent intoxication occurred within the 2 years before the clinical onset of chronic solvent-induced neurocognitive disorder;\n\nNote: acute solvent intoxication and Specified List 2 of solvents are defined in the Schedule 1 - Dictionary.\n\n(4) having an episode of acute solvent intoxication due to a solvent from the Specified List 3 of solvents, with evidence of associated persistent brain damage on imaging, at the time of the clinical onset of chronic solvent-induced neurocognitive disorder;\n\nNote: acute solvent intoxication and Specified List 3 of solvents are defined in the Schedule 1 - Dictionary.\n\n(5) inability to obtain appropriate clinical management for chronic solvent-induced neurocognitive disorder.\n\n10 Relationship to service\n\n(1) The existence in a person of any factor referred to in section 9, must be related to the relevant service rendered by the person.\n\n(2) The factor set out in subsection 9(5) applies only to material contribution to, or aggravation of, chronic solvent-induced neurocognitive disorder where the person's chronic solvent-induced neurocognitive disorder was suffered or contracted before or during (but did not arise out of) the person's relevant service.\n\n11 Factors referring to an injury or disease covered by another Statement of Principles\n\nIn this Statement of Principles:\n\n(1) if a factor referred to in section 9 applies in relation to a person; and\n\n(2) that factor refers to an injury or disease in respect of which a Statement of Principles has been determined under subsection 196B(2) of the VEA;\n\nthen the factors in that Statement of Principles apply in accordance with the terms of that Statement of Principles as in force from time to time.\n\n \n\n \n\nSchedule 1 - Dictionary \n\nNote: See Section 6\n\n1 Definitions\n\nIn this instrument:\n\n acute solvent intoxication means clinically significant problematic behavioural or psychological changes (for example, belligerence, assaultiveness, apathy, impaired judgement) that develop during or shortly after, short-term, high-dose exposure to a solvent by inhalation, ingestion or dermal contact. These changes are accompanied by 2 or more of the following signs or symptoms that also develop during or shortly after solvent exposure:\n\n(a) blurred vision or diplopia;\n\n(b) depressed reflexes;\n\n(c) dizziness;\n\n(d) euphoria;\n\n(e) generalised muscle weakness;\n\n(f) incoordination;\n\n(g) lethargy;\n\n(h) nystagmus;\n\n(i) psychomotor retardation;\n\n(j) slurred speech;\n\n(k) stupor or coma;\n\n(l) tremor; or\n\n(m) unsteady gait;\n\n where the signs or symptoms are not attributable to another medical condition and are not better explained by another disorder of mental health, including substance use disorder due to intoxication with another substance.\n\n chronic solvent-induced neurocognitive disorder—see subsection 7(2).\n\n DSM-5 means the American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Arlington, VA, American Psychiatric Association, 2013.\n\n MRCA means the Military Rehabilitation and Compensation Act 2004.\n\n relevant service means:\n\n(a) operational service under the VEA;\n\n(b) peacekeeping service under the VEA;\n\n(c) hazardous service under the VEA;\n\n(d) British nuclear test defence service under the VEA;\n\n(e) warlike service under the MRCA; or\n\n(f) non-warlike service under the MRCA.\n\nNote: MRCA and VEA are also defined in the Schedule 1 - Dictionary.\n\n severe substance use disorder means a disorder of mental health characterised by a problematic pattern of use of a substance leading to clinically significant impairment or distress, as manifested by at least 6 of the following criteria, occurring within a 12-month period:\n\n(a) the substance is often taken in larger amounts or over a longer period than was intended;\n\n(b) there is a persistent desire or unsuccessful efforts to cut down or control substance use;\n\n(c) a great deal of time is spent in activities necessary to obtain the substance, use the substance, or recover from its effects;\n\n(d) craving, or a strong desire or urge to use the substance;\n\n(e) recurrent substance use resulting in a failure to fulfil major role obligations at work, school, or home;\n\n(f) continued substance use despite having persistent or recurrent social or interpersonal problems caused or exacerbated by the effects of substances;\n\n(g) important social, occupational, or recreational activities are given up or reduced because of substance use;\n\n(h) recurrent substance use in situations in which it is physically hazardous;\n\n(i) continued substance use despite knowledge of having a persistent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by the substance; or\n\n(j) tolerance, defined by either:\n\n(i) a need for markedly increased amounts of the substance to achieve intoxication or desired effect; or\n\n(ii) a markedly diminished effect with continued use of the same amount of the substance.\n\n Specified List 1 of solvents means:\n\n(a) bromomethane;\n\n(b) butane;\n\n(c) carbon disulphide;\n\n(d) dichloromethane;\n\n(e) dichloroethane;\n\n(f) ethyl acetate;\n\n(g) petrol;\n\n(h) styrene;\n\n(i) tetrachloroethylene;\n\n(j) toluene;\n\n(k) trichloroethylene;\n\n(l) white spirit; or\n\n(m) xylene.\n\n Specified List 2 of solvents means:\n\n(a) bromomethane;\n\n(b) carbon disulphide;\n\n(c) dichloroethane;\n\n(d) dichloromethane;\n\n(e) ethyl acetate;\n\n(f) styrene;\n\n(g) tetrachloroethylene;\n\n(h) toluene;\n\n(i) trichloroethylene;\n\n(j) white spirit; or\n\n(k) xylene.\n\n Specified List 3 of solvents means:\n\n(a) bromomethane;\n\n(b) carbon disulphide;\n\n(c) chloromethane;\n\n(d) dichloromethane;\n\n(e) dichloroethane;\n\n(f) ethyl acetate;\n\n(g) ethylene glycol;\n\n(h) styrene;\n\n(i) tetrachloroethylene;\n\n(j) toluene;\n\n(k) trichloroethylene;\n\n(l) white spirit; or\n\n(m) xylene.\n\n terminal event means the proximate or ultimate cause of death and includes the following:\n\n(a) pneumonia;\n\n(b) respiratory failure;\n\n(c) cardiac arrest;\n\n(d) circulatory failure; or\n\n(e) cessation of brain function.\n\n VEA means the Veterans' Entitlements Act 1986.\n\n \n\n \n","sortOrder":0}],"analysis":{"flash_summary_failed":{"failed":true,"reason":"A positive credit balance is required for all requests, including BYOK, so fallback providers remain available. Add credits at https://vercel.com/d?to=%2F%5Bteam%5D%2F%7E%2Fai%3Fmodal%3Dtop-up to continue.","source":"analysis-cron"},"flash_summary":{"complexity_score":7,"scope_assessment":{"changed":true,"description":"Yes. The instrument repeals the 2013 Statement (s4) and replaces the earlier framing of ‘chronic solvent encephalopathy’ with a DSM‑5‑aligned definition of ‘chronic solvent‑induced neurocognitive disorder’ and new, specific exposure and evidentiary thresholds (s7(2); s9; Schedule 1). It therefore narrows and re‑specifies the medical and exposure criteria applied to VEA/MRCA claims (s5), altering the practical scope of cases that will satisfy a ‘reasonable hypothesis’. "},"complexity_factors":["Technical medical diagnostic criteria derived from DSM‑5 that require standardised neuropsychological testing and exclusion of other causes (s7(2)(a)(i), (vii)).","Multiple, distinct exposure thresholds and pathways that satisfy the test (severe substance use disorder; chronic daily exposure; 50 acute intoxication episodes; single acute episode with imaging evidence) (s9(1)–(4)).","Three overlapping but different specified solvent lists (Lists 1–3) with slightly different inclusions, affecting which exposures qualify under particular factors (Schedule 1, Specified Lists).","Temporal and cessation rules (eg. 5‑year periods, onset within 1 year of cessation, last episode within 2 years) impose precise timing burdens on proof (s9(1)–(3)).","Interaction with other Statements of Principles and cross‑references to other injury/disease SOPs creates dependency on changing external instruments (s11).","Application limited to claims under defined statutory provisions (section 120A VEA or section 338 MRCA), narrowing administrative context (s5).","Replaces an earlier instrument (s4), meaning prior case‑law or evidentiary expectations may not map directly to the new criteria.","A discretionary legal standard — raising a ‘reasonable hypothesis’ — combines legal judgement with specialised medical evidence, concentrating decision authority in medical and administrative assessors (s3, s9)."],"plain_english_summary":"This instrument repeals the earlier Statement of Principles and sets the medical and exposure criteria the Repatriation Medical Authority uses to form a “reasonable hypothesis” that chronic solvent‑induced neurocognitive disorder (and death from it) is connected to a person’s relevant service. It applies to claims under the VEA and the MRCA, lists diagnostic requirements, exposure thresholds and specified solvent lists, and excludes alcohol‑ or medication‑induced disorders. Decision‑makers apply these criteria to determine entitlement; claimants must supply the clinical and exposure evidence the instrument requires."},"kimi_summary":{"content_quality":"ok","complexity_score":6,"scope_assessment":{"changed":true,"description":"The original 2013 instrument covered 'chronic solvent encephalopathy' — a narrower, more traditional medical concept. This 2021 version significantly expands scope by adopting the DSM-5 framework of 'substance-induced neurocognitive disorder', which: (1) broadens the cognitive domains assessed beyond traditional 'encephalopathy' concepts; (2) explicitly includes specific diagnostic pathways for acute intoxication episodes and substance use disorders, not just chronic occupational exposure; (3) adds three distinct chemical lists with different exposure thresholds, creating multiple pathways to establish connection; and (4) incorporates modern neuropsychological testing requirements. The shift from 'encephalopathy' to 'neurocognitive disorder' represents a substantial medical-legal expansion aligned with contemporary psychiatry rather than neurology alone."},"complexity_factors":["Multiple nested definitions: 12 defined terms in Schedule 1, with several cross-referencing each other (e.g., 'acute solvent intoxication' defined with 13 sub-criteria, 'severe substance use disorder' with 10 criteria including nested tolerance definitions)","Three separate 'Specified Lists' of solvents with overlapping but distinct chemical inventories (List 1: 13 substances, List 2: 11 substances, List 3: 13 substances) — requires careful comparison to determine which exposure pathway applies","Complex temporal requirements in section 9: multiple time-based conditions ('within 5 years', 'more days than not for at least 5 years', 'within 1 year of cessation', '50 episodes within 2 years', 'within 2 years before')","Conditional logic in factor (2): requires both exposure pattern AND cessation timing condition ('if exposure has ceased...then that onset occurred within 1 year')","Diagnostic criteria in section 7(2) incorporate external medical standard (DSM-5) by reference with 7 specific sub-criteria including exclusion clauses","Section 11 creates dynamic incorporation of other Statements of Principles by reference ('as in force from time to time'), creating interdependent regulatory web","Dual statutory framework application (VEA and MRCA) with six distinct service categories defined"],"plain_english_summary":"This replaces the 2013 “solvent encephalopathy” policy with modern DSM‑5‑based medical criteria for chronic solvent‑induced neurocognitive disorder, defining it as irreversible, measurable cognitive decline clearly attributable to solvent exposure rather than other causes.\n\nIt affects veterans, current/former defence members and peacekeepers exposed to industrial solvents and sets the legal threshold for entitlement and rehabilitation under the VEA and MRCA — excluding alcohol‑ or medication‑related brain damage."}},"importantCases":[],"_links":{"self":"/api/acts/statement-of-principles-concerning-chronic-solvent-induced-neurocognitive-disorder-reasonable-hypoth","history":"/api/acts/statement-of-principles-concerning-chronic-solvent-induced-neurocognitive-disorder-reasonable-hypoth/history","analysis":"/api/acts/statement-of-principles-concerning-chronic-solvent-induced-neurocognitive-disorder-reasonable-hypoth/analysis","conflicts":"/api/acts/statement-of-principles-concerning-chronic-solvent-induced-neurocognitive-disorder-reasonable-hypoth/conflicts","importantCases":"/api/acts/statement-of-principles-concerning-chronic-solvent-induced-neurocognitive-disorder-reasonable-hypoth/important-cases","documents":"/api/acts/statement-of-principles-concerning-chronic-solvent-induced-neurocognitive-disorder-reasonable-hypoth/documents"}}